Stock Events

Stock Events

Search...

Hard to Treat Diseases

$0

1

-$0-95% Thursday 16:39

Statistics

Day High

0

Day Low

0

52W High

0

52W Low

0

Volume

1

Avg. Volume

15

Mkt Cap

0

P/E Ratio

0

Dividend Yield

-

Dividend

-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HTDS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Gilead Sciences

Gilead Sciences focuses on antiviral drugs to treat diseases like HIV, hepatitis B, hepatitis C, and influenza, directly competing in the treatment of hard-to-treat diseases.

Vertex Pharmaceuticals

Vertex Pharmaceuticals is known for its treatments for cystic fibrosis, a hard-to-treat genetic disorder, making it a direct competitor in the field of complex diseases.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals specializes in medicines for serious conditions, including a range of hard-to-treat diseases, through its innovative biotechnology.

Amgen focuses on human therapeutics, including treatments for illnesses considered hard to treat, such as cancer and cardiovascular disease.

Biogen targets neurological and neurodegenerative diseases, competing in the space of hard-to-treat conditions with its advanced therapies.

AbbVie works on significant chronic diseases like rheumatoid arthritis, psoriasis, Crohn's disease, and other hard-to-treat conditions, making it a competitor.

Novartis offers diversified medications, including treatments for hard-to-treat diseases across several therapeutic areas, competing on a broad scale.

Pfizer develops and produces medicines and vaccines for a wide range of medical disciplines, including hard-to-treat diseases, making it a key competitor.

Merck is known for its contributions to healthcare, including vaccines and treatments for hard-to-treat diseases, positioning it as a competitor.

Johnson & Johnson

Johnson & Johnson, through its pharmaceutical division, addresses a wide array of health conditions, including hard-to-treat diseases, making it a competitor in the healthcare sector.

About

Hard to Treat Diseases Inc. manufactures, supplies, and exports biopharmaceuticals and vaccines in China and internationally. The company offers biologicals, including reteplase (rPA), mycobacterium vaccae, acutobin urinary kallidinogenase, ulinastatin, and cerebroprotein hydrolysate for injection; chemicals, such as cobratide injection, entecavir capsule, HES, dasatinib tablets, thymosin a1 for injection, imipenem and cilastatin sodium for injection, and meropenem for injection; and vaccines, which include rabies vaccine, ACYW135 meningococcal vaccine, influenza vaccine, Hepatitis A, and varicella vaccine. It markets its products through a sales network that focuses on South Asia, South-east Asia, Central and South America, and the Middle East. Hard to Treat Diseases Inc. was founded in 2009 and is based in Shenzhen, China.

Show more...

CEO

Shimin Yuan

Country

US

ISIN

US41164A1034

Listings

0 Comments

Share your thoughts

FAQ

What is Hard to Treat Diseases stock price today?▼

The current price of HTDS is $0 USD — it has decreased by -95% in the past 24 hours. Watch Hard to Treat Diseases stock price performance more closely on the chart.

What is Hard to Treat Diseases stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Hard to Treat Diseases stocks are traded under the ticker HTDS.

In which sector is Hard to Treat Diseases located?▼

Hard to Treat Diseases operates in the Health Care sector.

When did Hard to Treat Diseases complete a stock split?▼

Hard to Treat Diseases has not had any recent stock splits.

Where is Hard to Treat Diseases headquartered?▼

Hard to Treat Diseases is headquartered in Clearwater, US.